X-Biotix Pharmaceuticals

X-Biotix Therapeutics was a private U.S. biotechnology company focused on discovering first-in-class small molecule antibiotics for multidrug-resistant Gram-negative pathogens. The company was spun out of X-Chem and applied DNA-encoded library screening plus antibacterial medicinal chemistry to identify novel compounds against essential bacterial targets, including LpxA and LpxC in the lipopolysaccharide biosynthetic pathway. Its programs remained in discovery and early preclinical development, with no clinical-stage assets disclosed. In April 2021, the company announced a strategic shift that suspended active antibacterial research while it pursued publications, intellectual property strengthening, and potential out-licensing or new funding opportunities. Third-party company databases now describe the business as closed.